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Abstract
Objective and design The skin retention and penetration
characteristics of copper applied as glycyl-L-histidyl-L-
lysine cuprate diacetate were evaluated in vitro in order to
assess the potential for its transdermal delivery as anti-
inﬂammatory agent.
Materials and methods Flow-through diffusion cells with
1c m
2 exposure area were used under inﬁnite dose condi-
tions. 0.68% aq. Copper as a tripeptide was applied on
isolated stratum corneum, on heat-separated epidermis and
on dermatomed skin. Receptor ﬂuid collected over 48 h in
4 h intervals was analyzed by inductively coupled plasma
mass spectrometry for copper in tissues and receptor ﬂuid.
Results The permeability coefﬁcient of the compound
through dermatomed skin was 2.43 ± 0.51 9 10
-4 cm/h;
136.2 ± 17.5 lg/cm
2 copper permeated 1 cm
2 of that tis-
sue over 48 h, while 82 ± 8.1 lg/cm
2 of copper were
retained there as depot.
Conclusions Applied tansdermally as the tripeptide on
human skin ex vivo, copper permeated the skin and was
also retained in skin tissue in amounts potentially effective
for the treatment of inﬂammatory diseases.
Keywords Absorption  Arthritis  Bioavailability 
Copper complex  Depot  Inﬂammation
Introduction
Acute and chronic inﬂammation are characterized by
changes in the metabolism of copper and by a pronounced
responsiveness to therapy with copper compounds [1, 2].
The copper content and ceruloplasmin activity of serum are
signiﬁcantly elevated above normal values in inﬂammatory
diseases in humans and laboratory animals, and copper in
widely different chemical forms is used as therapeutic
agent in therapy for chronic and acute inﬂammation [2].
The rise in total serum copper measured in inﬂammation is
held to represent the natural anti-inﬂammatory response of
the organism itself. The responsiveness of inﬂammatory
disorders to copper supplementation suggests that the
control exerted by endogenous copper on inﬂammation is
susceptible to enhancement by exogenous sources. When
copper complexes were administered subcutaneously in
experimentally inﬂamed animals the reduction in inﬂam-
mation was proportional to total amount of copper injected
[3].
While for nearly three-quarters of a century water sol-
uble gold salts have been administered for their anti-
inﬂammatory properties, most effective among them gold
thiomalate, particularly to relieve the symptoms of juvenile
and adult rheumatoid arthritis [4], just how the metal exerts
its anti-arthritic effect is not clear as it does not have a
known biological function itself. Also, since the inception
of systemic therapy using gold compounds the incidence of
allergic skin reactions to the metal has been remarkably
high, attributed to induced hypersensitivity [5]. However,
recently Stoyanov and Brown [6] attributed an indirect role
played by gold. They found that it speciﬁcally binds to a
copper-activating protein, thus turning on production of a
protein pump involved in copper transport thus mobilizing
endogenous copper reserves stored mostly in liver and
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may thereby consist in their effect on copper management
in eukaryotic systems.
We investigated possible transdermal dosing of copper
as the alternative to what so far has been the therapy for
inﬂammatory disorders relying on intra articular or intra
muscular injection of drugs which comports considerable
patient discomfort.
Data on human skin penetration by copper compounds
are scarce. The percutaneous absorption of copper from
copper chloride and copper sulfate were investigated in
vitro on human skin by Pirot et al. [7]. Formulated for
therapeutic purposes, the salts were compounded with zinc
chloride and zinc sulfate in petrolatum and two aqueous
gels. For both the apparent permeability coefﬁcients Kp
were similar: 3.2–4.5 9 10
-6 cm/h. Extensive investiga-
tions conducted over years by Pickart into the multiple
functions of the human tripeptide glycidyl-L-histidyl-L-
lysine as its copper 2? complex (GHK-Cu), recently
reviewed [8], made that molecule an obvious choice for our
skin penetration study.
Using a model membrane made of stratum corneum
lipids, Mazurowska had suggested that copper peptides,
and GHK-Cu in particular, might permeate skin [9].
However, experiments using skin models generally
underestimate absorption since the composition of model
membranes does not reﬂect the structure of the stratum
corneum, a heterogeneous, multi component membrane,
nor does it account for the high hydrophilicity of GHK-Cu
which may determine an idiosyncratic path of diffusion
[10, 11]. Orth [12] and Finkey [13] measured uptake of
copper into superﬁcial facial skin strata in vivo when
applying GHK-Cu for cosmetic purposes, but to date bio-
availability of copper was not studied quantitatively using
human skin ex vivo. Therefore, evidence that copper does
penetrate the skin in any form is so far based on its
observed effects only: anti-inﬂammatory activity by topical
application of copper complexes was shown in animals by
Brown [1], by Sorenson in man [2], and has extensively
been reviewed by Milanino [14].
Materials and methods
Materials
The permeant was GHK-Cu (Ac)2, received from the
ProCyte Corp. (Kirkland, WA). It was not analyzed for
stoichiometric purity since, in several studies, copper
complexes in a physiological environment were subject to
de-complexation and rearrangement, depending on pH
and complex stability constants [15, 16]. Those investi-
gations indicated the presence of multiple species for
GHK-Cu (e.g., tri- and hexa-peptide) in solutions, toge-
ther with copper-free oligopeptide. Copper as a transition
metal of variable oxidation states has the ability to form
complexes with different geometries and stability. Here
the test compound is summarily referred to as GHK-Cu.
Concentrations are reported in terms of copper per ml of
solution.
Chemical: Glycyl-L-histidyl-L-lysine copper cuprate, diacetate GHK-
Cu (Ac)2, Formula: C18H29CuN6O8
Experimental design
In vitro (a.k.a. ex vivo) skin diffusion studies were con-
ducted with GHK-Cu at 0.68% aq. concentration using
glass cells to mimic in vivo permeant ﬂux. Copper depot
formation and penetration was studied using:
Isolated stratum corneum (Experiment A)
Entire epidermis, including stratum corneum (experi-
ment B)
Split thickness skin comprising stratum corneum, epi-
dermis and underlying dermis tissue (experiment C)
Tissue preparation
Human cadaver skin was obtained from the Northern
California Transplant Bank (San Rafael, CA) and stored in
a freezer (-20C) until use. All experiments were per-
formed within 2 months after freezing. Subjects were 3
Caucasian, aged 21–53 years, and both genders were
represented.
Split thickness skin (entire epidermis with a portion of
the dermis) was obtained by use of a dermatome targeted to
500 lm and stored (-20C) until use.
Entire epidermis, (isolated epidermis including stratum
corneum), was obtained by heat separation (60C) from
underlying dermis tissue and stored (-20C) until use.
Isolated stratum corneum was obtained from isolated
epidermis which was placed on Whatman paper soaked in a
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Chemical, St. Louis, USA) solution in 0.15 M phosphate
buffered saline (PBS, pH 7.4, Sigma) for 2 h at 37C.
Remaining trypsin activity was blocked by submerging the
stratum corneum sheet in 0.05% w/w trypsin inhibitor
Typed II (from soybean, Sigma Chemicals, St. Louis,
USA), then the stratum corneum sheet washed twice in
puriﬁed water, dried and stored above silica gel at room
temperature.
Diffusion experiment
Ex vivo skin tissue was obtained from three donors. Rep-
licates were run on tissue from the same donor. Glass low -
volume ﬂow cells with 0.8 cm
2 exposure area were kept at
37C. Receptor ﬂuid was collected over 48 h in 4 h inter-
vals. Cells were mounted in the wells of aluminum cell
holder (Stratacor, Richmond, CA), whose internal channels
were perfused with water at 37C from a circulating water
bath, and holders mounted on a fraction collector. Distilled
water containing 1 ml/l of gentamicin sulfate solution
(l00 mg/ml, Sigma, St. Luis, MO) was pumped through the
cells at approximately 2 ml/h with a 12 channel peristaltic
pump. Tissues were cut into circles with a biopsy punch
(1 cm
2), mounted on the diffusion cells and the donor
chambers clamped in place.
To test for tissue integrity, prior to the experiment with
tissue discs clasped in place the peristaltic pump was run at
10 rpm generating back pressure in the receptor cells (ﬁve
times the normal pressure) for 2 h to check for leakers,
which were eliminated.
About 1 ml of test solution was placed in the donor
chambers,closedwithgroundglassstoppersandsealedwith
Paraﬁlm to prevent donor solution evaporation. Eight cells
were typically set up at one time, with four cells used for
each of two treatments. Receptor ﬂuid samples were col-
lectedina20-mlpolyethylenescrew-capscintillation(LSC)
vials (Maxi-vial, Packard Instruments, Downers Grove, IL).
Atcompletionofanexperimentthedonorcellcontentswere
pipetted intoLSCvials.Thedonorchamberandskinsurface
was rinsed (3 9 2 ml) with distilled water and the rinse
saved in the LSC vials with polyethylene cap liners (Perkin-
Elmer, Shelton, CT). Nitric acid (0.75 g) was added to each
skin sample and the vial heated (50–60C) to effect disso-
lution. After cooling, samples were diluted with 15 ml
distilled water to give a ﬁnal nitric acid concentration of
3.5% required for inductively coupled plasma mass spec-
troscopy analysis. Samples were ﬁltered and stored at 4C.
Analytical methodology
For original copper levels, portions of isolated stratum
corneum, isolated epidermis, as well as split thickness
dermis were analyzed to determine the increment retained
there during diffusion. Following the diffusion experiment
C, split thickness skin was also separated into epidermis
and dermis (entire separated epidermis and separated der-
mis) for analysis of tissue depot formation in the
experiment.
Experimental details and results are reported in terms of
copper, analyzed by inductively coupled plasma mass
spectroscopy. It is a technique applicable to lg/l (ppb)
concentrations of many elements in aqueous medium upon
appropriate sample preparation of biological materials.
Reliability of the method for elemental analysis is based
upon multi-laboratory performance compared with that of
either furnace atomic absorption spectroscopy or ICP-AES.
Normal instrument detection limit for copper can be
anticipated at 0.5 ppb.
Inductively coupled plasma mass spectroscopy analyses
were performed by DuPont Analytical Solutions, Wil-
mington, DE. There samples were prepared by diluting
1:10 (volume/volume), using 2% HNO3 immediately prior
to analysis. The ICP-MS equipment used was an Agilent
7500c, operated under helium collision gas mode. The
instrumental detection limit was \100 pg/ml copper.
Standard solutions were prepared by diluting a 1,000-lg/ml
copper stock solution with 2% HNO3. Two separate (low
concentration and high concentration) six-point external
calibration curves (r
2[0.999) were used for quantitation
of both copper isotopes (63 and 65 Cu) with 89Y used as an
internal standard. The low concentration calibration curve
was constructed from 1, 2, 5, 10, and 20 ng/ml Cu stan-
dards and the high concentration calibration curve was
from 20, 100, 1,000, 5,000, and 10,000 ng/ml copper
standards. The instrument was calibrated using the ﬁve
standards above, and the samples bracketed between the
standards without extrapolation either below the calibration
curve nor above it.
Data analysis
The permeability coefﬁcient Kp (cm/h) is the ratio of
steady state ﬂux and the donor concentration multiplied by
the membrane area covered. The ﬂux (lg/cm
2/h) at steady
state (Jss) is the permeant value per membrane area per
hour following the initial lag time which is the delay
measured for the permeant to reach a constant value Jss.
The Kp was calculated from the permeation rate at steady
state ﬂux Jss, determined from the linear portion of the
amount permeated versus time proﬁle. The permeation
proﬁle of copper for each tissue layer was plotted against
time.
The tissue copper levels reported from diffusion exper-
iments were corrected for endogenous levels determined
prior to the experiments.
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Skin permeability coefﬁcients (Kps) for the copper tri-
peptide ranged from 3 9 10
-7 cm/h through isolated
epidermis (Table 1, Exp. B), to 5.59 9 10
-3 cm/h through
isolated stratum corneum (Table 1, Exp. A).
Lag times measured from 2 h on isolated stratum cor-
neum and spilt thickness skin (Table 1, Exp. A, C), to 7 h
on isolated epidermis (Table 1, Exp. B).
Copper collected in the receptor ﬂuid in 48 h ranged
from 0.60 ± 0.21 lg/cm
2 or 0.006 ± 0.001% of the dose
through isolated epidermis (Exp. B; Table 2), to
136.2 ± 17.5 lg/cm
2 or 2.0 ± 0.31% through split thick-
ness skin (Exp. C, Table 2).
About 290 ± 69 lg/cm
2 Copper was retained in the
stratum corneum tissue, a 438-fold increase over baseline
levels (Table 3, Exp. A). Isolated epidermis retained
61.1 ± 13.1 lg/cm
2, a factor of 165 over base line
(Table 3, Exp. B), and dermatomed skin 53 ± 8.1 lg/cm
2
or 31 times baseline (Table 3, Exp. C).
Discussion
This study evaluates absorption and skin retention of a
copper tripeptide in separate skin compartments: the stra-
tum corneum, entire epidermis and split thickness skin.
The amount of copper deposited from the tripeptide in
the stratum corneum as well as in the entire epidermis and
dermis is signiﬁcant. For instance, about a 400-fold
increase over baseline was retained in the isolated stratum
corneum. Such high tissue retention of copper may be
attributed to intradermal decomplexation and re-binding to
various endogenous amino acids of higher nucleophilic
donor capacity than the original ligand.
Assessing whether permeant retained in skin tissues, the
stratum corneum in particular, eventually becomes avail-
able systemically is an issue of ongoing discussions.
Reservoir formation in the course of in vitro studies has
been addressed [17]. Retained drug may be lost to natural
desquamation, limiting its eventual systemic availability.
On closer analysis, however, it has been found that the
Table 1 Copper skin penetration as function of skin strata from aq.
GHK-Cu solution. Skin permeability coefﬁcients (Kp), steady-state
skin penetration ﬂux and lag time for copper tripeptide are shown for
isolated stratum corneum, total epidermis and split thickness
(dermatomed) human skin, respectively
Exp. Skin strata Kp 9 10
4 (cm/h) ± SD Flux (lg/cm
2/h) ± SD Lag time (h)
A Isolated stratum corneum (n = 3) 55.9 ± 13.2 38 ± 92
B Isolated epidermis (n = 3) 0.003 ± 0.0006 0.002 ± 0.0004 7
C Dermatomed skin (n = 8) 2.43 ± 0.51 1.7 ± 0.35 2
Difference in values were considered signiﬁcant (P\0.05)
Table 2 Human skin retention and penetration of copper in function of skin strata
Exp. Skin strata Donor
recovered
Stratum
corneum
Total
epidermis
Dermatomed
skin
Receptor ﬂuid Total %
recovered
A Isolated stratum corneum (n = 3) (79 ± 13) 290.3 ± 69 NA NA 2110 ± 589 (19.85 ± 3.9) (98 ± 27)
B Total epidermis (n = 3) (94 ± 12) ND 61.1 ± 13.1 NA 0.60 ± 0.21 (0.006 ± 0.001) (95 ± 12)
C Dermatomed skin (n = 8) (91 ± 14) ND ND 82 ± 8.1 136.2 ± 17.5 (2.0 ± 0.31) (94 ± 7)
Amount of copper found in the stratum corneum, total epidermis, dermatomed skin, receptor ﬂuid, donor compartment as well as the total amount
recovered are given in lg per cm
2 and in percentages of the applied copper dose (in brackets) after 48 h. Difference in values were considered
signiﬁcant (P\0.05)
NA not applicable; ND not determined
Table 3 Copper reservoir in skin layers vs. original levels from 0.68% aq. GHK-Cu at 48 h
Skin compartment Cu at 0 h (lg/cm
2)C u a t 4 8 h ( lg/cm
2) Increase vs. 0 h
Isolated stratum corneum (Exp. A) 0.68 ± 0.3; n = 3 290 ± 69; n = 3 4389
Total epidermis (Exp. B) 0.37 ± 0.2; n = 3 61.1 ± 13.1; n = 3 1659
Dermatomed skin (Exp. C) 1.72 ± 0.5; n = 85 3 ± 8.1; n = 83 1 9
Baseline copper levels and copper levels after 48 h exposure to 0.68% copper peptide solution are given for stratum corneum, total epidermis and
split thickness (dermatomed) skin. The difference in values were considered signiﬁcant (P\0.05)
986 J. J. Hostynek et al.fraction of chemical sloughing off versus the part that
becomes systemically available depends on the ratio of lag
time to the turnover time for the stratum corneum [18].
Accordingly, at least 80% of the amount in the stratum
corneum will become available if the lag time for pene-
tration through that tissue is less than approximately 16 h
This corresponds to 5% of the typical stratum corneum
turnover time of 14 days. Consequently, based on our
results where lag times ranged from 2 to 7 h, the copper
retained in the stratum corneum has the potential to
become systemically available also. As a result of the
experiment with dermatomed skin, by topical application
of GHK-Cu under the present conditions 200–250 lg/cm
2
copper may become systemically available. Since the
experiment was conducted ex vivo, it is possible that even
larger amounts will be retained in the deeper dermal tissue
in vivo, to be followed by further diffusion.
The permeation rate of GHK-Cu through stratum cor-
neum seems high, the highest of all three skin strata
studied, consistent with a model of porous transport.
Appendageal penetration is considered to be one, if not the
predominant pathway for the diffusion of multipolar ions
[19, 20]. In addition, the high penetration level through
isolated stratum corneum can be attributed to the absence
of retention in underlying skin, which would limit copper
penetration.
The marked hydrophilicity of the copper tripeptide with
a pseudo logPow =- 4.5, the quotient saturated n-octanol/
saturated aqueous solution [21], is reconcilable with shunt
penetration typical for highly hydrophilic solutes such as
salts. Signiﬁcant penetration through appendages can occur
within minutes following exposure in contrast to non-
appendageal pathways [22, 23].
The Kps of GHK-Cu through epidermis and derma-
tomed skin were lower by about one order of magnitude.
Restriction of the pores area may be the cause for the
discrepancy in those diffusion constants when compared to
stratum corneum alone.
The present study indicates that topical administration of
copper as the tripeptide may offer an effective alternative
to injection. Since a realistic dimension for topical appli-
cation of GHK-Cu as a patch may cover 10 cm
2 of skin,
based on our results 1.36 mg of copper would then become
available over 48 h.
When administering copper for therapeutic purposes, the
potential for toxicity should be considered. There is ample
evidence that the copper ion released will be subject to the
highly efﬁcient homeostatic control in eukaryotic organ-
isms, preventing its circulation at toxic levels. Free ionic
copper, a relatively toxic metal, is moderated to the mini-
mum levels sufﬁcient for physiological needs, reported in
the range of 10
-11 to 10
-19 mol estimated in plasma, by
binding to ceruloplasmin and metallothionein [24]. The
dynamic equilibrium between ceruloplasmin and metallo-
thionein stored in liver tissue prevents toxic accumulation
of free copper ion in mammals [25]. That hepatic reservoir
is released slowly back into the blood as ceruloplasmin and
copper metallothionein in response to inﬂammation due to
injury or arthritis [26]. The average level of bound copper
in human control plasma is 1.12 lg/ml [27]; in arthritic
patients it is 1.40 lg/ml [28]. A therapeutically effective
copper level in inﬂammation cannot be assessed in deﬁnite
terms, however, because copper status induced in response
to inﬂammatory diseases in humans varies depending on
target organ [14]. In order to document the tolerability of
metallic copper in contact with the skin, which must ﬁrst be
oxidized in order to penetrate, Gorter examined absorption
and tolerance of metallic copper-containing ointments on
human volunteers over a period of several weeks. Copper
analysis in serum showed that levels had increased sig-
niﬁcantly above control levels, without overt untoward
effects, either in the skin or systemically, following
application of ointments containing up to 20% of the metal
in its elemental form [29].
Conclusions
The results obtained show that a topical organic copper
complex such as GHK-Cu may be an alternative to copper
delivery by injection, also potentially providing a skin
reservoir likely to become available over time. This effect
warrants further development toward transdermal delivery
of the anti-inﬂammatory agent, especially when consider-
ing GHK as ligand, a nature identical carrier tripeptide [8].
In the past, several laboratories demonstrated local and
systemic anti-inﬂammatory activity of copper compounds
by oral, ip, iv, and particularly subcutaneous administra-
tion. Having shown permeation of the skin barrier by
GHK-Cu in a therapeutically effective dose, however,
application of this principle to transdermal dosing may now
offer a realistic alternative to current, traditional thera-
peutic routes and agents. Taking our results a step further,
one can optimize the controlled release of copper for anti-
inﬂammatory therapy using patch technology with
well-designed formulations. This would present a welcome
alternative to current methods, which rely on corticoste-
roids, NSAIDs, chrysotherapy, or the family of COX-2
cyclooxygenase inhibitors as analgesics and anti-inﬂam-
matory agents, since most of them are associated with
untoward side effects [30–32], some of them causing
considerable discomfort, depending on the mode of
administration.
That a deﬁcit in this essential element may be substan-
tially corrected by choosing an appropriate cupriphore
represents a signiﬁcant outcome of our endeavors towards
Human skin retention and penetration 987alleviating rheumatoid arthritis and similar musculoskeletal
conditions afﬂicting the general population.
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